A scathing U.S. Senate investigation has exposed how the Cleveland Clinic, one of the nation's most prestigious healthcare systems, harvested nearly $1 billion from a federal drug discount program intended for low-income and cancer patients — while deploying those resources toward lavish executive pay, international expansion, sports partnerships, and fine art.
The Senate Health, Education, Labor, and Pensions (HELP) Committee report found that Cleveland Clinic generated approximately $933.7 million in savings and revenue through the 340B program between 2018 and 2023. The program was established by Congress to help safety-net hospitals "stretch scarce Federal resources" to serve vulnerable patients. Instead, the committee found no direct benefits passed to patients at the point of care.
According to nonprofit tax filings and the Senate probe, the money was directed elsewhere. Multiple executives earned seven-figure compensation packages — with CEO Dr. Tomislav Mihaljevic reportedly receiving over $6 million annually, and top officers earning millions more. Investigative reporting has identified dozens of Cleveland Clinic executives in the "$1 million club."
Meanwhile, the system invested heavily in non-core expansions. Its 7,000-piece art collection, maintained by a full curatorial staff, adorns its facilities. The clinic deepened a 25-year partnership with the Cleveland Cavaliers, breaking ground on a 210,000-square-foot Global Peak Performance Center — a state-of-the-art NBA practice facility on the Cuyahoga Riverfront. And thousands of miles away, Cleveland Clinic Abu Dhabi stands as a monument to international brand expansion.
All while serving over 10,000 cancer patients — many of whom qualify for charity care — and defending the 340B windfall as necessary to offset operational costs.
Cleveland Clinic has argued that Congress never mandated 340B savings go directly to patients, claiming the funds support charity care, community benefit programs, and capital improvements. But the Senate report flatly rejects that logic, noting the program's growth has outpaced any measurable benefits for the uninsured or underinsured populations it was designed to protect.
Drug pricing analysts note the ultimate cost is passed along to consumers and government programs, meaning taxpayers and struggling patients are effectively subsidizing executive enrichment and global empire-building.
For cancer patients navigating crushing medical debt, the revelation is a gut punch. Advocacy groups are now demanding strict auditing, beneficiary-level reporting, and legislative reform to ensure 340B resources reach bedside — not boardrooms.
The scandal amplifies a growing national debate over whether mega-nonprofit health systems have lost sight of their charitable mission. When taxpayer-supported institutions build art collections and NBA practice facilities while low-income oncology patients absorb full-sticker drug costs, critics say the word "nonprofit" has lost its meaning.
